Buradasınız

Anasayfa » Content

Normoglisemik Obez Hastalarda Prolaktin ve İnsülin Direnci İlişkisi

The Relationship Between Insulin Resistance And Serum Prolactin Levels in Normoglycemic Obese Patients

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In the present study we aimed to investigate the correlation between insulin sensitivity and serum prolactin levels in normoglycemic obese patients. Thirty-six subjects, with varying degrees of BMI (BMI=39.7±5.4) (22 obese and 14 morbide obese patients) were included in this study. All subjects underwent a diagnostic protocol which included measurements of insulin sensitivity index, serum prolactin levels and anthropometric measures. The insulin sensitivity was measured by HOMA (Homeostasis Model Assessment) score. Correlation analysis showed that there was no significant relationship among serum prolactin levels and HOMA-IR (r=-0.25, p=0.27). There was a significant relationship among serum prolactin levels and BMI (r=0.52, p<0.05). There was a significant difference in serum prolactin levels between obese and morbide obese patients (p<0.05). These results show that the circulating prolactin elevation, which is observed during body mass increase, does not reflect insulin resistance. Further studies will be required to investigate the role of prolactin in obesity pathogenesis.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada; normoglisemik obez hastalarda, insülin duyarlılığı ile serum prolaktin düzeyleri arasındaki ilişkiyi araştırmayı amaçladık. VKİ değişen oranlarda olan (VKİ=39,7±5,4) 36 olgu (22 obez ve 14 morbid obez) çalışmaya dahil edildi. Tüm olgulara; insülin duyarlılık indeksi, serum prolaktin düzeyleri ve antropometrik ölçümlerden oluşan tanısal protokol uygulandı. İnsülin duyarlılığı HOMA skoru ile ölçüldü. Korelasyon analizi, serum prolaktin düzeyleri ile HOMA-IR arasında (r=-0.25, p=0.27) herhangi bir ilişki olmadığını gösterdi. Serum prolaktin düzeyleri ile VKİ arasında (r=0.52, p<0.05) anlamlı bir bağlantı mevcuttu. Obez ve morbid obez hastalar arasında serum prolaktin düzeyleri yönünden anlamlı farklılık saptandı (p<0.05). Bu sonuçlar göstermiştir ki, vücut kitlesi arttıkça gözlenen dolaşımdaki prolaktin yüksekliği, insülin direncini yansıtmamaktadır. Obezite patogenezinde prolaktinin rolünün araştırıldığı daha ileriki çalışmalara ihtiyaç duyulmaktadır.
FULL TEXT (PDF): 
PDF icon arastirmax-normoglisemik-obez-hastalarda-prolaktin-insulin-direnci-iliskisi.pdf
  • 3
85-87
  • Turkish

REFERENCES

References: 

1. Bjorntorp P: Neuroendocrine perturbations as a cause of insulin
resistance. Diabetes Metab Res Rev 1999; 15(6): 427-41.
2. Bjorntorp P, Rosmond R: Neuroendocrine abnormalities in
visceral obesity. Int J Obes Relat Metab Disord 2000; 24(2): 80-5.
3. Kopelman PG: Physiopathology of prolactin secretion in obesity.
Int J Obes Relat Metab Disord 2000; 24(2): 104-8.
4. Haffner SM, Miettinen H, Stern MP: The homeostasis model in
the San Antonio Heart Study. Diabetes Care 1997; 20(7): 1087.
5. Golda V, Fickova M, Pinterova L, Jurcovicova J, Macho L, Zorad
S: Terguride attenuates prolactin levels and ameliorates insulin
sensitivity and insulin binding in obese spontaneously
hypertensive rats. Physiol Res 2001; 50(2): 175-82.
6. Baptista T, Lacruz A, Meza T, Contreras Q, Delgado C, Mejias
MA, Hernandez L: Antipsychotic drugs and obesity: is prolactin
involved? Can J Psychiatry 46(9): 829-834, 2001.
7. Withers DJ. Insulin receptor substrate proteins and
neuroendocrine function. Biochem Soc Trans 2001; 29(4): 525-9.
8. Toprak S, Yonem A, Cakir B, Guler S, Azal O, Ozata M, Corakci
A: Insulin resistance in nonobese patients with polycystic ovary
syndrome. Horm Res 2001; 55(2): 65-70.
9. Nielsen JH, Galsgaard ED, Moldrup A, Friedrichsen BN,
Billestrup N, Hansen JA, Lee YC, Carlsson C: Regulation of beta-cell mass by hormones and growth factors. Diabetes 2001; 50
(Suppl 1): 25-9.
10. Fleenor DE, Freemark M: Prolactin induction of insulin gene
transcription: roles of glucose and signal transducer and activator
of transcription 5. Endocrinology 2001; 142(7): 2805-10.
11. Fruchtman S, Gift B, Howes B, Borski R: Insulin-like growth
factor-I augments prolactin and inhibits growth hormone release
through distinct as well as overlapping cellular signaling
pathways. Comp Biochem Physiol 2001; 129: 237-42.
12. Kopelman PG: Physiopathology of prolactin secretion in obesity.
Int J Obes Relat Metab Disord 2000; 24 (Suppl 2): 104-8.
13. Greenman Y, Tordjman K, Stern N: Increased body weight
associated with prolactin secreting pituitary adenomas: weight
loss with normalization of prolactin levels. Clin Endocrinol (Oxf)
1998; 48(5): 547-53.
14. Kamath V, Jones CN, Yip JC, Varasteh BB, Cincotta AH, Reaven
GM, Chen YD: Effects of a quick-release form of bromocriptine
(Ergoset) on fasting and postprandial plasma glucose, insulin,
lipid, and lipoprotein concentrations in obese nondiabetic
hyperinsulinemic women. Diabetes Care 1997; 20(11):1697-701.

Thank you for copying data from http://www.arastirmax.com